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Abstract 
Background 
Patients with schizophrenia have significant cognitive deficits, which may 
profoundly impair quality of life. These deficits are also evident at the 
neurophysiological level with patients demonstrating altered Event Related 
Potentials (ERPs) in several stages of cognitive processing compared to 
healthy controls; within the auditory domain, for example, there are replicated 
alterations in Mismatch Negativity (MMN), P300, and Auditory Steady State 
Response (ASSR). However, currently there are no approved pharmacological 
treatments for cognitive deficits in schizophrenia.  
Aims 
Here we examine whether the PDE4 (phosphodiesterase-4) inhibitor, 
roflumilast, can improve neurophysiological deficits in schizophrenia.  
Methods 
Using a randomised, double-blind, placebo-controlled, crossover design study 
in 18 patients with schizophrenia, the effect of the PDE4 inhibitor, roflumilast 
(100µg and 250µg) on ASSR (early stage), MMN and theta (intermediate stage) 
and P300 (late stage) was examined using EEG. A total of 18 subjects were 
randomised and included in the analysis.  
Results 
 4 
Roflumilast 250µg significantly enhanced the amplitude of both the MMN 
(p=0.04) and working memory-related theta oscillations (p=0.02) compared to 
placebo but not in the other (early or late stage) cognitive markers.  
Conclusions 
The results suggest that PDE4 inhibition, with roflumilast, can improve EEG 
cognitive markers, which are impaired in schizophrenia, and that PDE4 
inhibition acts at an intermediate rather than early or late cognitive processing 
stage. This study also underlines the use of neurophysiological measures as 
cognitive biomarkers in experimental medicine. 
Funding 
This work was supported by Takeda Pharma A/S, London.  
Clinical Trials Registration  
This trial was pre-registered at clinicaltrials.gov. Study Title: “Roflumilast Plus 
Antipsychotics Proof of Mechanism Study in Schizophrenia”. Identifier: 
NCT02079844. URL: https://clinicaltrials.gov/ct2/show/NCT02079844 
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Introduction 
Patients with schizophrenia show significant cognitive deficits in multiple 
domains of cognitive functioning (Kern et al., 2011) which have a major negative 
impact on patients’ day to day lives (Narvaez et al., 2008; Sensky et al., 2000). 
These deficits impair function and do so even more than positive symptoms 
(Green, 1966). Despite this and evidence that a number of compounds may 
improve cognition, there are still currently no approved medications to improve 
cognition in schizophrenia (Gilleen, 2017; Keefe, 2019). Current ‘antipsychotic’ 
medications which principally act via dopamine D2 receptors, also fail to 
improve cognition (Percudani et al., 2004). Thus, there is an urgent need to 
develop treatment strategies that improve cognitive functioning in this patient 
group.  
PDE4 inhibitors offer a potential new line of treatment for these deficits. PDE4 
inhibitors target one of eleven members of a family of intracellular enzymes that 
hydrolyse the cyclic nucleotide cyclic adenosine monophosphate (cAMP), thus 
raising cAMP levels. CAMP plays an important role as a second messenger 
molecule controlling multiple cellular processes (Pérez-Torres et al., 2000). 
Modulators of cAMP are promising therapeutic targets for schizophrenia as 
studies have shown impairments in levels of cAMP and cAMP signalling in the 
brains of people with schizophrenia (Garver et al., 1982; Muly, 2002; Tardito et 
al., 2000).  
PDE4 may be particularly relevant for the treatment of schizophrenia, since it 
regulates cAMP levels in the axon terminal afferents to the striatum (Heckman 
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et al., 2016). Evidence has been accumulating to indicate that PDE4 inhibitors 
can remediate cognitive deficits, particularly memory deficits in animals (Barad 
et al., 1998; Hosseini-Sharifabad et al., 2012; Vanmierlo et al., 2016) including 
in primates (Rutten et al., 2008) in a rodent model of psychosis (Wiescholleck 
and Manahan-Vaughan, 2012) and most recently in patients with schizophrenia 
(Gilleen et al., 2018). 
Improved task performance can be the result of changes at any point in task 
process from sensory detection to response selection and motor output and it 
is unclear whether PDE4 leads to improvements across the processing chain 
or at specific processing stages. One way to explore this issue is through the 
measurement EEG biomarkers, increasingly used in psychiatric and 
pharmacological studies (Light et al., 2012; Wilson and Danjou, 2015) and used 
previously to examine PDE4 inhibition in a preclinical hyperdopaminergic model 
of schizophrenia (Halene and Siegel, 2008; Maxwell et al., 2004). This approach 
offers valuable utility in identifying early indicators for prediction of potential 
efficacy (18).  
In schizophrenia three EEG measures have been shown to be consistently 
reduced, which, based on the temporal profile and component frequencies, 
correspond approximately to: i) early sensory processing - 40 Hz Auditory 
Steady State Response (ASSR) (Kwon et al., 1999; O’Donnell et al., 2013; 
Thuné et al., 2016); ii) intermediate processing - Mis-Match Negativity (Erickson 
et al., 2016; Kasai et al., 1999) and iii) late processing – posterior P300 (or P3b) 
(Hirayasu et al., 1998; Winterer et al., 2003). The 40 Hz ASSR arises from the 
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resonant response of neural circuits to auditory clicks presented at a frequency 
in the gamma range and assesses the integrity of sensory pathways. MMN is a 
fronto-centrally distributed negative potential evoked by a regularity violation in 
a repeating series of stimuli. The auditory MMN ERP is independent of attention 
and smaller MMN amplitudes are associated with poorer cognitive function in 
schizophrenia (Baldeweg et al., 2004; Light et al., 2015). The P300 is a later 
ERP component evoked in similar tasks to the MMN that require a response. It 
is thought to relate to the updating of contextual memory (Donchin and Coles, 
1988) and inhibition of extraneous brain activation, amongst other processing 
functions (Polich, 2007).  
In addition to these measures we also explored the effects of roflumilast on 
prefrontal theta (3.5-7 Hz) spectral power, which reflects coordination of brain 
networks and cognitive control (Cavanagh and Frank, 2014) and has been 
shown to underpin memory in both humans and experimental animals (for 
reviews see (Hsieh and Ranganath, 2014; Johnson and Knight, 2015)). Theta 
is linked to anterior cingulate function and sustained attention (Gevins et al., 
1997); and increases parametrically with working memory load (Jensen and 
Tesche, 2002; Raghavachari et al., 2001) and is reduced in schizophrenia 
(Schmiedt et al., 2005).  
Here we report the EEG findings of a study testing PDE4 enhancement of 
cognition in schizophrenia using roflumilast. This study also included a cognitive 
test battery and MRI assessments, which have been reported separately 
(Gilleen et al., 2018). The specific predictions were that roflumilast would 
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increase the magnitude of these EEG measures known to be dysfunctional in 
schizophrenia, and that the pattern of enhancement would help determine the 
processing stage modulated by roflumilast. 
Methods and Materials 
Study Design 
This was a randomized, double-blind, placebo-controlled, single-site, 3-period 
crossover study to evaluate the effect of roflumilast as an add-on to second 
generation antipsychotics. The study consisted of three counter-balanced 8-day 
treatment periods separated by washout intervals of at least 14 days (beginning 
immediately after dosing on Day 8; see figure 1 for study schedule of activities). 
Randomisation codes, assigned sequentially to participants at the 
randomisation stage, dictated treatment order of low and high dose roflumilast 
and placebo. For information on drug treatment sequences, compliance, 
plasma, exposure and safety see Supplementary Materials. EEG recordings 
were obtained prior to dosing on Day 1 and approximately 5 hours 
(approximately mid-afternoon) after dose on Day 8 for each of the three dosing 
periods. 
Participants 
Participants were men or women aged 18 to 60 years, inclusive, who met 
Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5 
Association, 2013)) criteria for schizophrenia, were cognitively impaired, and 
were on a stable dose of second-generation antipsychotic medication for at 
least 2 months prior to screening. Participants continued taking second 
 9 
generation antipsychotic medication at a stable dose and regimen throughout 
the study and were clinically stable with mean PANSS scores changing by fewer 
than 6 points across the study assessment points. Exclusion criteria are 
provided in Supplementary Materials. Consent was conducted in accordance 
with Good Clinical Practice, and specifically, for this vulnerable patient group, a 
psychiatrist conducted a Capacity To Consent assessment before consent was 
requested. Briefly, this involves a participant being able to understand and 
explain back what they are being asked to do in the study. 
This research was conducted at the Institute of Psychiatry, Psychology and 
Neuroscience at Kings College London, UK and in accordance with the protocol 
procedures complied with the Declaration of Helsinki, the International 
Conference on Harmonisation (ICH) E6 GCP guidance, and all applicable local 
or regional regulatory requirements. The study was pre-registered with 
clinicaltrials.gov (identifier: NCT02079844) and ethics approvals were given by 
NRES Committee South Central-Berkshire (reference: 12/SC/0443). 
Sample 
31 participants were screened, 21 of whom were randomized, and 15 
completed all the EEG sessions (see Supplementary Materials for drop-out 
information). Three more participants completed at least one period (including 
both Day 1 and Day 8). All 18 participants were included in the statistical 
analysis (see table 1 for sample baseline demographic and clinical information). 
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EEG Acquisition 
EEG was acquired using a Compumedics Neuroscan SYNAMPS 2 amplifier, 
with 64 channels. A linked ear recording reference was used, and additional 
electrodes were added on the left and right Mastoids as well as horizontal and 
vertically around the eyes, in order to capture eye movement artefacts. A 
sampling rate of 5kHz was used, and the low pass and high pass filters were 
set at 1kHz and 0.05 Hz respectively. Impedances were kept below 10 kΩ.  
EEGs were recorded in the early afternoon, and the study day also included 
fMRI, cognitive assessment and questionnaires, reported elsewhere (Gilleen et 
al., 2018).  
Paradigms 
ASSR 
Click trains at frequencies of 40 Hz, 30 Hz and 20 Hz were played through 
earphones. Each click train was 800ms long and inter-train interval was 
between 1050ms and 1150ms. For each frequency, there were 55 click trains. 
Participants were asked to keep their eyes closed during this task. 
MMN 
Unlike the P300, the MMN paradigm does not require a response to the deviant 
tone. The standard stimuli was a tone of duration frequency 1000 KHz and 
duration 150 ms, whilst the deviant had the same frequency, but a duration of 
100 ms. The fixed interstimulus interval was 500 ms. There were 150 deviants, 
with a probability of occurrence of 0.2. The participants were asked to pay 
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attention to a silent video, and if they became drowsy and/or closed their eyes, 
they were prompted to wake up. 
P300  
The P300 is a positive event related potential, which occurs around 300 ms 
after a target tone to which the participant is required to make a response. The 
target tone was at a frequency of 1500 Hz, whereas the standard tone was at a 
frequency of 1000Hz. Both tones had durations of 200ms. The probability of a 
target tone was 16%, with 39 targets. The time between tones was varied 
randomly between 1 and 1.5 seconds. The participants were required to 
maintain gaze on a fixation cross during this paradigm. 
N-Back Working Memory task 
Strings of letters were sequentially presented on the screen every 1 second with 
a 2 second inter-stimulus interval. There were four different conditions indicated 
by instruction on the screen: “Is it an X?” indicated that the participants were 
required to press a key when they saw the letter X; “1-back” indicated that a 
response was required if the letter was the same as the previous letter, whereas 
in the “2-back” and “3-back” conditions the participants responded if the letter 
was the same as the one two letters or three letters previously, respectively. 
EEG analysis 
Preprocessing 
Using Neuroscan 4.5 analysis software, the EEG was re-referenced to the 
average of Mastoid channels. For the MMN, P300 and theta amplitude 
 12 
measures, blink artefacts were corrected using the regression method (Croft 
and Barry, 2000). For the ASSR, power line noise was corrected using noise-
cancellation and muscular artefacts were corrected using mathematical 
modelling and subtraction of muscle spikes (Nottage et al., 2013). Occasionally, 
the signal from a faulty channel, in a particular EEG recording for a participant, 
needed to be replaced by a signal reconstructed from nearby channels. In such 
a case exactly the same reconstructed channel was used for analysis of all EEG 
recordings from that participant. 
ASSR 
Epochs of length 819.2ms were cut, from 25 to 844ms after the start of each 
click train, and the linear trend was removed. Epochs with greater than +/-70 
µV amplitude at Cz were rejected. The epochs were averaged to give an ERP 
at 40 Hz. A Fast Fourier transform was carried out on each ERP, using a 20% 
Hanning window and the evoked amplitude in the 39.06-40.28Hz frequency bin 
was obtained. 
MMN 
The MMN was calculated at FZ with an average mastoid reference. A low pass 
20 Hz filter and a 1 Hz high pass filter were used, following published 
recommendations (Duncan et al., 2009), both being zero phase shift filters with 
12dB roll-offs. These filters will not distort the MMN, as the power of this ERP 
is almost entirely in the theta band (Lee et al., 2017). The baseline was set as  
-75 ms to +5 ms. Epochs with amplitude greater than +/- 70 µV at Fz were 
rejected. An ERP was calculated from all standard tones except the tone 
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following each deviant; a separate ERP was calculated for the deviant tones. 
The ERPs were exported to MATLAB for the remaining calculations. The 
standard average was subtracted from the deviant average, to give a difference 
wave. As the MMN is part of the MMN/P3a complex (Hermens et al., 2010), 
which has both positive and negative components, it is not suited to the mean 
area under the curve method of quantification. We therefore used an automated 
peak detection algorithm in MATLAB. 
An unbiased estimate of each individual participant’s ERP was estimated by 
averaging the ERPs from all 6 sessions for each participant and finding the 
highest amplitude negative peak in the difference wave. Since a 100ms duration 
deviant was used, whereas the standard tone was 150ms, the deviance begins 
at 100ms after the start of the tone. Therefore, a late time window is used for 
the MMN (Umbricht et al., 2000) of 200ms to 340ms after the start of the tone. 
For each session, the largest negative peak within 70 ms of the latency of the 
individual’s mean MMN, but within the 200-340 ms window was taken as the 
MMN value for that session. 
P300 
A 45 Hz, a 12dB zero phase-shift low pass filter was applied, after which epochs 
were cut from -200 before each oddball tone to 1000 ms after. The epochs were 
baseline corrected using -150 to 0ms as the baseline. Epochs with greater than 
+/- 100 µV in PZ were rejected. An average ERP was created, which was 
exported into MATLAB. For each session the mean amplitude in the +280ms to 
+420ms time window was calculated.  
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Working Memory 
The working memory analysis was restricted to 2-back condition, which is the 
more commonly-used condition analysed. This provides sufficient WM 
challenge while data in the 3-back condition indicated that a number of 
participants were unable to engage sufficiently at such a high working memory 
level. The EEG was cut into 3276.8 ms segments, from 638.2 ms prior to the 
presentation of each letter in the N-back task, to 2638.4 ms after it, and the 
linear trend was removed. Epochs with amplitude greater than +/- 70 µV at FZ 
were rejected. Fast Fourier Transforms were carried out using a 10% Hanning 
window, and the mean theta (3.5–7 Hz) amplitude at FZ was calculated in the 
2-back condition. Percentage errors in the 2-back condition were calculated as 
the number of false alarms plus the number of missed targets, divided by the 
total number of possible targets and multiplied by 100.  
Statistical Analysis 
In the main statistical analysis a Mixed Model approach was used, with Subject 
as a Random Effect. This means that the differences between theta amplitudes 
across participants is taken into account by the model. However, if we used raw 
mean theta amplitudes and error rates in the regression, the differences 
between participants would confound the analysis. In order not to reduce the 
signal to noise ratio (Kenward and Roger, 2010) baseline (Day 1) values were 
not subtracted from Day 8 values for that period. Instead, as recommended 
(Kenward and Roger, 2010), baseline data were used to increase the precision 
of the estimate of each participants EEG measures. The baselines are also 
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treated as outcome variables but without associated treatment effects. Pairwise 
comparisons between active treatment groups and placebo were generated 
within the framework of analysis of variance (ANOVA), with Day (1 or 8), and 
Dose (0, 100 µg, 250 µg) as categorical fixed effects. Subject, nested within 
sequence to control for period effects, was included as a random effect. The 
least-squares means, p-values, and 2-sided 95% confidence intervals for the 
pairwise comparisons will be presented.  
The aim was to determine if there was sufficient evidence of drug signal on EEG 
measures. Given this desire to avoid Type II errors, adjustment was not made 
for multiple comparisons - results do not survive multiple-comparison 
correction. Effect sizes were calculated to compare active treatment groups to 
placebo using Cohen’s d (Cohen, 1988). 
Association between reductions in working memory theta and error 
performance in the 2-back condition were assessed by Pearson’s product 
moment correlation coefficient. To reduce the effect of inter-subject variability 
baseline corrected values from participants who had completed all sessions 
were used. The baseline error rate and theta amplitudes for each participant 
were calculated as the mean of all the Day 1 sessions for that participant. The 
mean baseline percentage error for each person was subtracted from each 
session value. However, as the magnitude of EEG amplitudes can vary 
substantially between subjects due to non-neural factors such as skull thickness 
and as the magnitude of differences in theta amplitude, from baseline, will also 
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be affected by such factors the oscillation magnitudes were divided by baseline 
magnitudes.  
Results 
Auditory Steady-State Response 
There were no statistically significant differences for the 40Hz ASSR amplitude. 
While 40Hz ASSR with 100 µg roflumilast (0.316 ±0.038µV) tended to be larger 
than with placebo (0.270 ±0.025 µV), with a moderate effect size (Cohen’s 
d=0.344) this difference was not significant (F=1.24, p=0.270, df=60.9). The 
40Hz ASSR amplitude was also unchanged by roflumilast 250 µg (0.280 ±0.046 
µV), (Cohen’s d=0.067, F =0.064, p=0.801, df=57.1).  
Mismatch Negativity 
MMN amplitudes at Fz were significantly larger with roflumilast 250 µg (-2.007 
±0.245 µV) than with placebo (-1.492 ±0.168 µV), (F=4.40, p=0.040, df=61.2) 
and the effect size was moderate to large (Cohen’s d=0.614). Even with the 
lower 100 µg dose of roflumilast the MMN amplitudes were larger and effect 
size was moderate (Cohen’s d=0.438, Mean= -1.846±0.231µV) although this 
effect was not significant (F=1.916, p=0.171, df=64.2). 
P300 
There was no significant difference in P300 amplitudes at Pz between 
roflumilast 250 µg (4.56±1.06µV) and placebo (4.11 ±1.75 µV, F=0.30, p=0.587, 
df=58.4) and the effect size was small (Cohen’s d=0.06). The P300 amplitude 
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was also not changed by roflumilast 100 µg (Mean= 4.33±1.0µV, Cohen’s 
d=0.05, F=0.06, p=0.804, df =60.6). 
Theta amplitude in the working memory task 
Prefrontal theta amplitude in the 2-back condition of the working memory task 
was significantly increased by roflumilast 250 µg (0.94±0.13 µV) compared with 
placebo (0.83 ±0.12 µV, F=5.46, p=0.023, df=59.7) and the effect size was 
small to moderate (Cohen’s d=0.25). The 100 µg dose of roflumilast had no 
effect on the prefrontal theta amplitude (0.83±0.12 µV) compared with placebo 
(Cohen’s d=0.00, F<0.01, p=0.998, df=61.8). 
Working memory task performance 
The post-drug baseline corrected theta amplitude was found to be negatively 
correlated with the baseline corrected 2-back percentage errors on Day 8 
(Correlation Coefficient = -0.316, p=0.037) but not on Day 1 (Correlation 
Coefficient =-0.064, p=0.682). Although the trend for both doses was towards 
fewer errors, compared to placebo (mean percentage errors = 62.8± 10.5 %), 
neither 250 µg roflumilast (mean percentage errors = 41.4 ± 15.0 %, F=2.18, 
p=0.145, df=57.3) nor 100 µg roflumilast (mean percentage errors = 40.3 ± 9.7 
% (F=2.10, p=0.153, df=62.8) had a statistically significant effect on the 
percentage errors. The effect sizes for accuracy were moderate for both doses 
(roflumilast 250 µg: Cohen’s d= -0.420, roflumilast 100 µg: Cohen’s d=-0.405).  
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Discussion 
The present study examined the potential for roflumilast to improve EEG 
biomarkers of cognitive impairment in schizophrenia. Mis-match negativity, 
shown to be reduced in schizophrenia (Erickson et al., 2016), was significantly 
improved with 250 µg roflumilast and with a medium-large effect size (0.61). 
This dose of roflumilast also significantly enhanced frontal theta associated with 
working memory functioning. No effect of roflumilast, at either dose, was seen 
on P300 or ASSR ERPs, nor on working memory performance itself.  
MMN reflects sensory memory processing and occurs when violations in 
environmental regularity happen regardless of attention. Hence, MMN may 
index the capacity for short-term sensory memory traces (Giard et al., 1990). 
Recently, EEG was used to show that roflumilast improves a neural signal 
linked to attentional sensory gating in healthy volunteers (Heckman et al., 2018) 
and improves the P600 associated with improved verbal memory in young 
healthy adults (Van Duinen et al., 2018). Our study demonstrated increased 
MMN ERPs, which may indicate that PDE4 inhibition increases neural signals 
to represent currently-relevant environmental information at low-level 
attentional states. Heckman et al. (Heckman et al., 2018) propose that neuronal 
tuning to environmental stimuli is improved by PDE4’s capacity to modulate the 
reciprocity of GABA-ergic inhibitory interneurons and pyramidal neurons as they 
respond to environmental stimuli, and alter (‘gate’) their firing response to 
subsequent stimuli. Elevated dopamine neurotransmission (as in 
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schizophrenia) negatively affects such processes and so dopamine-related 
disturbances in low-level processing could be modulated by PDE4 inhibition.  
As PDE4 inhibition increases intracellular cAMP levels in striatum and frontal 
cortex it was expected that roflumilast would improve WM, which relies, in part, 
on the fronto-striatal circuit (McNab and Klingberg, 2008). Theta is a distributed 
network rhythm (Başar et al., 2001) thought to coordinate and control activity in 
different brain areas (Cavanagh and Frank, 2014), and is related to WM 
efficiency (Raghavachari et al., 2001; Tóth et al., 2014). Roflumilast (at 250ug) 
significantly improved prefrontal theta; and while higher theta predicted fewer 
errors, WM error rates were not significantly better  (vs placebo). Earlier data 
from our group (Gilleen et al., 2018) provided preliminary evidence that 
roflumilast may reduce prefrontal cortical demands during spatial working 
memory as assessed with fMRI, in a dose-depenent manner. Taken together, 
while WM performance was not significantly improved (nor a different spatial 
span task reported previously (Gilleen et al., 2018)), the changes seen in 
prefrontal activity (with fMRI; Gilleen et al., 2018), and elevated prefrontal theta 
during the Nback task (with EEG) indicate roflumilast has the potential to 
improve working memory ability.  
The potential to improve working memory performance aligns with evidence 
from pre-clinical pharmacological challenge (Egawa et al., 1997; Rutten et al., 
2008; Vanmierlo et al., 2016) which could be consistent with frontal theta 
effects. The effects may reflect Increase dopamine synthesis and turnover in 
striatum which may enhance the dopamine D1 receptor/PKA/DARPP-32 
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signalling cascade in frontal cortex. In animals, rolipram increases dopamine 
D1 receptor signaling in frontal cortical pyramidal neurons and dopamine D1 
receptor signalling and improves working memory performance (Castner and 
Goldman-Rakic, 2004. (Kuroiwa et al., 2012). The correlation between theta 
magnitude and performance suggests that theta oscillations may be involved in 
the remediation of working memory impairments by roflumilast. Future work 
should aim to further investigate these effects in a larger sample size as 
behavioural improvements would necessarily be harder to detect than drug 
effects on brain activity per se. 
PDE4 inhibition has been shown to impact on hippocampal activity in CA1 
(Barad et al., 1998; Navakkode et al., 2004; Wiescholleck and Manahan-
Vaughan, 2012) while hippocampal theta activity has been shown to increase 
with WM  demands (Tesche and Karhu, 2000). Theta oscillations may be 
indicative of encoding of information directly and rapidly into long-term memory 
via synaptic modification (Greenstein et al., 1988; Huerta and Lisman, 1993; 
Raghavachari et al., 2001) and play an important integrative role in working 
memory organization and cognitive coordination (See (Sauseng et al., 2010)). 
WM-related theta activity, evident during retention periods, may index a gating 
mechanism controlling WM task relevance (signal to noise ratio) (Raghavachari 
et al., 2001) reminiscent of the improvements in lower level ‘gating’ reported by 
Heckman et al. (Heckman et al., 2018).  
These results add to the growing evidence of the potential of PDE4 inhibitors 
as pro-cognitive agents and are consistent with positive effects on attention and 
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memory observed in preclinical (e.g. (Maxwell et al., 2004), and healthy human 
studies (Heckman et al., 2018; Van Duinen et al., 2018), including the significant 
improvements in verbal memory in schizophrenia that we recently reported 
(Gilleen et al., 2018). However, Roflumilast showed no effect on P300 
(specifically P3b) or ASSR suggesting PDE4 does not have an effect on this 
lower-level sensory response. Together therefore, roflumilast appears to have 
an effect on brain physiology, but its precise capacity to alter the individual’s 
brain function has yet to be fully determined.  
Limitations 
As this was a proof of concept study, the numbers of patients included were 
modest, and correction for multiple comparisons was not used, though 
directional predictions were made and pre-registered. Nevertheless, it is 
noteworthy that any numerical trends in the data for either drug dose, across all 
EEG measures, were all in the expected direction. The time-course of effects 
of roflumilast on the EEG measures could not be assessed as there was only 
one EEG recording after dosing for each period. Future studies could improve 
on these limitations by increasing the number of included patients and adding 
additional recordings. 
Conclusions 
This study demonstrates that 250 µg roflumilast increases the magnitude of 
MMN and of theta oscillations during working memory. Together with the 
cognitive and fMRI results from Gilleen et al. (Gilleen et al., 2018), roflumilast 
appears to ameliorate multiple types of sustained mental representation of 
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external, task-related, and environmental stimuli – but not contextual memory 
(as indexed by P300), nor in the entraining of neural firing to auditory frequency 
and phase (ASSR). In this study, the effects of high dose Roflumilast were 
specific to preattentional sensorial memory and working memory biomarkers. 
This study was a proof of concept study and should now be followed up by more 
research using a larger sample size. The fact that significant changes in EEG 
measures with a small number of subjects has been observed reinforces the 
usefulness of EEG in pharmacological studies as a marker of potential for 
efficacy (Wilson and Danjou, 2015). More importantly, these results add support 
to the proposition that PDE4 inhibitors have therapeutic potential in patients with 
schizophrenia. 
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